卵巢癌是严重威胁女性生命健康的妇科恶性肿瘤。2020年全世界约有31.4万新发病例,且约20.7万女性死于该疾病[1]。基于生物学行为的相似性,2014年国际妇产科联盟(International Federation of Gynecology and Obstetrics,FIGO)妇科肿瘤...卵巢癌是严重威胁女性生命健康的妇科恶性肿瘤。2020年全世界约有31.4万新发病例,且约20.7万女性死于该疾病[1]。基于生物学行为的相似性,2014年国际妇产科联盟(International Federation of Gynecology and Obstetrics,FIGO)妇科肿瘤学组将卵巢癌、输卵管癌和原发腹膜癌应用统一的标准进行分期。在2018年FIGO相关指南制订3年后,且综合大量研究结果,2021年FIGO[2]对这一疾病进行再次指南更新,所用分期依然沿用2014年分期标准[3]。展开更多
Objectives. To evaluate the efficacy and tolerability of ima-tinib mesylate (Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) in patients with recurrent ovarian and primary peritoneal cancer. Methods. This was a...Objectives. To evaluate the efficacy and tolerability of ima-tinib mesylate (Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) in patients with recurrent ovarian and primary peritoneal cancer. Methods. This was an open- label, single- institution phase II trial. Patients were eligible if they had measurable platinum/taxane- resistant disease, received 2- 4 prior treatment regimens, and over- expressed at least one imatinib target (c- Kit, PDGFR- β , or c- Abl) by immunohistochemistry. Imatinib was administered orally at 600 mg daily for 6 weeks (one course)- and was repeated in the absence of measurable progre-ssion. Results. Sixteen enrolled patients were evaluable for toxicity and 12 for response. The median number of prior treatments was 4. A total of 29 courses were initiated. No complete or partial responses were documented during a median follow- up of 6.6 months. However, 4 (33% ) of the 12 evaluable patients had stable disease lasting 3.8, 6.4, 7.5, and 8+ months. Expression of PDGFR- β and c- Abl was seen in 15 (94% ) and c- Kit in 8 (50% ) patients’ tumors. There was no relationship between best response (stable disease) and target expression. Adverse events were uncommon,with fatigue and nausea/vomiting being reported in 34% and 31% of cycles, respectively. Two patients underwent dose reduction for rash and edema (n = 1) and grade 3 neutropenia (n = 1). No grade 4 toxicity was observed. Conclusion. Imatinib mesylate was well tolerated but did not produce clinical responses in patients with previously treated metastatic ovarian and primary peritoneal carcinoma.展开更多
文摘卵巢癌是严重威胁女性生命健康的妇科恶性肿瘤。2020年全世界约有31.4万新发病例,且约20.7万女性死于该疾病[1]。基于生物学行为的相似性,2014年国际妇产科联盟(International Federation of Gynecology and Obstetrics,FIGO)妇科肿瘤学组将卵巢癌、输卵管癌和原发腹膜癌应用统一的标准进行分期。在2018年FIGO相关指南制订3年后,且综合大量研究结果,2021年FIGO[2]对这一疾病进行再次指南更新,所用分期依然沿用2014年分期标准[3]。
文摘Objectives. To evaluate the efficacy and tolerability of ima-tinib mesylate (Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) in patients with recurrent ovarian and primary peritoneal cancer. Methods. This was an open- label, single- institution phase II trial. Patients were eligible if they had measurable platinum/taxane- resistant disease, received 2- 4 prior treatment regimens, and over- expressed at least one imatinib target (c- Kit, PDGFR- β , or c- Abl) by immunohistochemistry. Imatinib was administered orally at 600 mg daily for 6 weeks (one course)- and was repeated in the absence of measurable progre-ssion. Results. Sixteen enrolled patients were evaluable for toxicity and 12 for response. The median number of prior treatments was 4. A total of 29 courses were initiated. No complete or partial responses were documented during a median follow- up of 6.6 months. However, 4 (33% ) of the 12 evaluable patients had stable disease lasting 3.8, 6.4, 7.5, and 8+ months. Expression of PDGFR- β and c- Abl was seen in 15 (94% ) and c- Kit in 8 (50% ) patients’ tumors. There was no relationship between best response (stable disease) and target expression. Adverse events were uncommon,with fatigue and nausea/vomiting being reported in 34% and 31% of cycles, respectively. Two patients underwent dose reduction for rash and edema (n = 1) and grade 3 neutropenia (n = 1). No grade 4 toxicity was observed. Conclusion. Imatinib mesylate was well tolerated but did not produce clinical responses in patients with previously treated metastatic ovarian and primary peritoneal carcinoma.
